A phase 3 trial of Scholar Rock’s spinal muscular atrophy (SMA) candidate has hit its primary endpoint, sparking a 200%-plus premarket surge in the biotech’s stock price. Investors went wild despite ...

The Leading Scholar program awards various levels of scholarships recognizing the leadership skills and academic success of applicants. While a select number of applicants will be invited to campus ...

Scholar Rock contends its experimental drug for spinal muscular atrophy can achieve what none of the currently available therapies can do to treat this rare disease. After positive data from a pivotal ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

The Kellogg Executive Scholar Certificate gives you the opportunity to earn a credential from a world-class business school, create a personalized leadership development path aligned with your unique ...

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings in ...

Oct 7 (Reuters) - Scholar Rock's (SRRK.O), opens new tab experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its ...

Posts from this author will be added to your daily email digest and your homepage feed. is a NYC-based AI reporter and is currently supported by the Tarbell Center for AI Journalism. She covers AI ...